Abacavir-induced liver toxicity

Maria Diletta Pezzani; Chiara Resnati; Valentina Di Cristo; Agostino Riva; Cristina Gervasoni

doi:10.1016/j.bjid.2016.03.002

Abacavir-induced liver toxicity

Braz J Infect Dis. 2016 Sep-Oct;20(5):502-4. doi: 10.1016/j.bjid.2016.03.002. Epub 2016 Apr 4.

Authors

Maria Diletta Pezzani¹, Chiara Resnati¹, Valentina Di Cristo¹, Agostino Riva², Cristina Gervasoni³

Affiliations

¹ Università di Milano, Luigi Sacco University Hospital, Department of Biomedical and Clinical Sciences L. Sacco, Milan, Italy.
² Università di Milano, Luigi Sacco University Hospital, Department of Infectious Diseases, Milan, Italy.
³ Università di Milano, Luigi Sacco University Hospital, Department of Infectious Diseases, Milan, Italy. Electronic address: [email protected].

Abstract

Abacavir-induced liver toxicity is a rare event almost exclusively occurring in HLA B*5701-positive patients. Herein, we report one case of abnormal liver function tests occurring in a young HLA B*5701-negative woman on a stable nevirapine-based regimen with no history of liver problems or alcohol abuse after switching to abacavir from tenofovir. We also investigated the reasons for abacavir discontinuation in a cohort of patients treated with abacavir-lamivudine-nevirapine.

Keywords: Abacavir; HIV; Liver toxicity.

Publication types

Case Reports
Review

MeSH terms

Adult
Anti-HIV Agents / adverse effects*
Antiretroviral Therapy, Highly Active / adverse effects*
Chemical and Drug Induced Liver Injury / etiology*
Dideoxynucleosides / adverse effects*
Female
HIV Infections / drug therapy
HLA-B Antigens / immunology
Humans
Retrospective Studies
Risk Factors
Treatment Outcome

Substances

Anti-HIV Agents
Dideoxynucleosides
HLA-B Antigens
HLA-B*57:01 antigen
abacavir